» Articles » PMID: 10696024

Comparison of Relative Cerebral Blood Volume and Proton Spectroscopy in Patients with Treated Gliomas

Overview
Specialty Neurology
Date 2000 Mar 1
PMID 10696024
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Elevated relative regional cerebral blood volume (rCBV) reflects the increased microvascularity that is associated with brain tumors. The purpose of this study was to investigate the potential role of rCBV in the determination of recurrent/residual disease in patients with treated gliomas.

Methods: Thirty-one rCBV studies were performed in 19 patients with treated gliomas. All patients also had proton MR spectroscopy and conventional MR imaging. Regions of abnormality were identified on conventional MR images by two neuroradiologists and compared with rCBV and MR spectroscopic data. Metabolites and rCBV were quantified and compared in abnormal regions.

Results: In high-grade tumors, rCBV values were proportional to choline in regions of tumor and nonviable tissue. Although the presence of residual/recurrent disease was often ambiguous on conventional MR images, the rCBV maps indicated regions of elevated vascularity in all low-grade tumors and in 12 of 17 grade IV lesions. Regions of elevated and low rCBV corresponded well with spectra, indicating tumor and nonviable tissue, respectively.

Conclusion: This study suggests that rCBV maps and MR spectroscopy are complementary techniques that may improve the detection of residual/recurrent tumor in patients with treated gliomas. Compared with the spectra, the rCBV maps may better reflect the heterogeneity of the tumor regions because of their higher resolution. The multiple markers of MR spectroscopy enable better discrimination between normal and abnormal tissue than do the rCBV maps.

Citing Articles

Evaluating the Efficacy of Perfusion MRI and Conventional MRI in Distinguishing Recurrent Cerebral Metastasis from Brain Radiation Necrosis.

Schack A, Aunan-Diop J, Gerhardt F, Pedersen C, Halle B, Kofoed M Brain Sci. 2024; 14(4).

PMID: 38671973 PMC: 11048647. DOI: 10.3390/brainsci14040321.


Salvage Treatment for Progressive Brain Metastases in Breast Cancer.

Spalek M, Mandat T Cancers (Basel). 2022; 14(4).

PMID: 35205844 PMC: 8870695. DOI: 10.3390/cancers14041096.


Brain tumor segmentation using 3D Mask R-CNN for dynamic susceptibility contrast enhanced perfusion imaging.

Jeong J, Lei Y, Kahn S, Liu T, Curran W, Shu H Phys Med Biol. 2020; 65(18):185009.

PMID: 32674075 PMC: 11744448. DOI: 10.1088/1361-6560/aba6d4.


Current Clinical Brain Tumor Imaging.

Villanueva-Meyer J, Mabray M, Cha S Neurosurgery. 2017; 81(3):397-415.

PMID: 28486641 PMC: 5581219. DOI: 10.1093/neuros/nyx103.


Post-treatment changes of tumour perfusion parameters can help to predict survival in patients with high-grade astrocytoma.

Sanz-Requena R, Revert-Ventura A, Garcia-Marti G, Salame-Gamarra F, Perez-Girbes A, Molla-Olmos E Eur Radiol. 2016; 27(8):3392-3400.

PMID: 27999986 DOI: 10.1007/s00330-016-4699-2.


References
1.
Fulham M, Bizzi A, Dietz M, Shih H, Raman R, Sobering G . Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology. 1992; 185(3):675-86. DOI: 10.1148/radiology.185.3.1438744. View

2.
Kennan R, Zhong J, Gore J . Intravascular susceptibility contrast mechanisms in tissues. Magn Reson Med. 1994; 31(1):9-21. DOI: 10.1002/mrm.1910310103. View

3.
Aronen H, Cohen M, Belliveau J, Fordham J, Rosen B . Ultrafast imaging of brain tumors. Top Magn Reson Imaging. 1993; 5(1):14-24. View

4.
Shimizu H, Kumabe T, Tominaga T, Kayama T, Hara K, Ono Y . Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol. 1996; 17(4):737-47. PMC: 8337269. View

5.
Rosen B, Belliveau J, Chien D . Perfusion imaging by nuclear magnetic resonance. Magn Reson Q. 1989; 5(4):263-81. View